Journal decision profile

Clinical Psychopharmacology and Neuroscience

Medicine · Psychology

Clinical Psychopharmacology and Neuroscience's 2026 Journal Metrics Score is 1.8, ranking Q2 in Psychiatry and Mental health. Two-year citation average from OpenAlex data, updated August 2026.

South KoreapISSN 1738-1088eISSN 2093-4327
Checking system sharing availability.Visit homepage

Bookmark this page — track observed submission-to-acceptance timing, FWCI and field-normalized citation data for this journal in one view.

Journal Metrics Score
i
Journal Metrics ScoreThe raw score is citations received in the latest complete year by works from the two previous years, divided by the number of those works. It is calculated from OpenAlex open data (CC0) and is not a percentage grade.
2026
1.8

Journal Metrics Score 2026 · 2021–2024 window citedness 2.81.

Submission-to-acceptance
i
Submission-to-acceptanceCalendar days between the received and accepted dates reported in recent PubMed records. This interval includes editorial handling and author revisions, so it is not time to first decision or pure peer-review time.
PUBMED
73 daysmedian

Middle 50%: 42–108 days

99 of 100 PubMed-indexed articles · 99% coverage · 2024–2025

Indicative APC
i
Indicative APCThis journal-level estimate comes from the OpenAlex source record. It is not a verified quote and may exclude taxes, waivers, society discounts, or article-type charges. Check the journal's official website before deciding.
OPENALEX · VERIFY
Not available

No journal-level APC is available in the current OpenAlex snapshot. Cost is excluded from scoring.

Free preview · no sign-in

Does your manuscript fit Clinical Psychopharmacology and Neuroscience?

Paste your title to see which of this journal's published topics it overlaps with. Your title stays in your browser for this preview and is not sent anywhere.

Want ranked journals with fit reasons, risks and a submission strategy instead? See a sample AI report.

At a glance

Journal decision profile

Each spoke is a 0–100 percentile within a comparable journal cohort—not a percentage grade or a single black-box rating.

Relative profile

Metrics ScoreThe raw 2026 Journal Metrics Score is the recent two-year citation average shown above. The radar converts it to a 0–100 cohort percentile: farther out means a higher score than more comparable journals. It is not a percentage grade.iSource outputThe raw rank compares lifetime output inside the journal’s leading-topic source set. The radar then compares that rank position across Decision Profile journals in the same primary OpenAlex field; when that field has too few profiles, it uses the broader profile set. Farther out means relatively more output, not better research quality.iTop 10% shareThe share of recent papers in the global top 10% for citations after comparing papers of the same type, publication year, and subfield. The radar converts that share to a 0–100 cohort percentile; it does not predict how a new paper will perform.iMedian FWCICitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected citation level for comparable papers; the radar shows its 0–100 cohort percentile.iSubmission-to-acceptanceCalendar days from the received date to the accepted date in recent PubMed records. This includes editorial handling and author revisions, so it is not the time to first decision and not pure peer-review time. The radar uses a 0–100 cohort percentile with shorter observed timing plotted farther out; it does not measure review quality.iOutput volumeAverage works published per year in the recent analysis window, converted to a 0–100 cohort percentile. Farther out means the journal publishes more papers; it does not mean those papers are better.i
Cost is intentionally excluded. Missing APC data is never converted to a zero-dollar fee or a fabricated cost score.

Raw values behind the shape

Always visible
Metrics Score
i
Metrics ScoreThe 2026 raw Journal Metrics Score shown above. The bar is its 0–100 percentile within the radar's comparable journal cohort; it is not a percentage score.
1.82026 · OPENALEX
Source output rank
i
Source output rankThis lifetime journal-wide output rank compares works published by the OpenAlex source with sources associated with the journal’s leading topic. More output does not mean higher quality.
#430 / 2,528LIFETIME OUTPUT
Highly cited papers
i
Highly cited papersShare of recent works in the global top 10% for citations after comparing papers of the same type, publication year, and subfield.
9.7%FIELD-NORMALIZED TOP 10%
Field-normalized impact
i
Field-normalized impactCitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected level for comparable work.
0.82MEDIAN FWCI
Submission-to-acceptance
i
Submission-to-acceptanceReceived-to-accepted calendar days from qualified PubMed records. It includes editorial handling and author revisions; it is not time to first decision or pure peer-review time.
73 daysIQR 42–108 DAYS
Recent output
i
Recent outputAverage works published per year across the complete analysis window. This is a volume measure, not a quality score.
88 / yr2021–2024 AVG
Field-normalized top 10% share9.7%

34 of 352 works · same type, year & subfield

Field-normalized top 1% share0.3%

1 works · same type, year & subfield

Median FWCI0.82×

Below field-year expectation

Source output rank#430

of 2,528 topic-associated OpenAlex sources by lifetime output

What does Median FWCI mean?

FWCI compares papers with the same publication year, type, and field. 1.0 is the world average; above 1.0 is above expectation. This journal's median is 0.82, so its typical recent paper runs about 18% below its field benchmark.

What does Top 10% Share mean?

9.7% of recent papers rank in the global top 10% after field normalization. This is easier to compare across specialties than raw citation totals.

Publishing pattern

Publication volume and article mix

Volume is separated from citation accumulation so newer papers are not presented as weaker simply because they are newer.

Works published by year

OpenAlex source records · 2016–2025

682016
692017
822018
742019
742020
872021
802022
1212023
642024
742025

Recent work-type mix

352 OpenAlex works · 2021–2024

Article81.8%
Review16.5%
Editorial0.9%
Letter0.6%
Erratum0.3%
OpenAlex article is broader than “original research.” PubMed Publication Types can add case-report and clinical-study detail.
Fit signals

Topics and research coverage

OpenAlex topics show the research communities this journal serves.

Leading OpenAlex topics

2021–2024 works
Schizophrenia research and treatment57
Treatment of Major Depression31
Attention Deficit Hyperactivity Disorder27
Bipolar Disorder and Treatment24
Transcranial Magnetic Stimulation Studies13
Dementia and Cognitive Impairment Research12
Obsessive-Compulsive Spectrum Disorders11
Suicide and Self-Harm Studies11
Autism Spectrum Disorder Research10
Electroconvulsive Therapy Studies8
Methodology: OpenAlex snapshot 2026-10-28. FWCI, percentile badges, topics, and type mix use 352 works published 2021–2024. Radar normalization is versioned in the cached profile, and no cost score is assigned without reliable APC data.

Subject Category Quartiles

Quartiles computed within each OpenAlex subfield
CategoryQuartile
Psychiatry and Mental healthQ2
Biological PsychiatryQ4
PharmacologyQ3

Is Clinical Psychopharmacology and Neuroscience a good journal?

A solid Q2 journal by citation data

By citation data, Clinical Psychopharmacology and Neuroscience is a solid journal: it is Q2 in Psychiatry and Mental health, the second quarter of journals by score, and ranks #625 of 1,171 Neuroscience journals by Journal Metrics Score (top 54%). Clinical Psychopharmacology and Neuroscience's 2026 Journal Metrics Score is 1.8. Recent papers took a median of 73 days from submission to acceptance, according to PubMed dates. OpenAlex classifies its papers in subfields including Psychiatry and Mental health, Biological Psychiatry, and Pharmacology, so check that your topic fits its scope.

Best quartile
Q2
Psychiatry and Mental health
Rank in Neuroscience
#625 of 1,171
Top 54%
2026 Journal Metrics Score
1.8
Acceptance rate
Not published
By the journal or publisher
Submission to acceptance
73 days
Median, PubMed records
Access model
Fully open access
No APC on record in OpenAlex
Papers published in 2025
74
OpenAlex works

Check before you submit

  • Confirm the journal is indexed where your institution or funder requires (for example Scopus or PubMed) before you submit.

Verdict from citation data only: quartile and field rank by Journal Metrics Score (OpenAlex), publisher-reported acceptance rates, and PubMed submission and acceptance dates. See how we rank journals and how to verify indexing.

Q2
Subfield Quartile
B4
CAS Block

Ranking and source check

#625
of 1,171 Neuroscience field journals
#164
among Q2 Neuroscience journals

Confirm the exact title and ISSNs against the publisher homepage before a high-stakes submission decision.

Journal Details

OpenAlex Works
1,076
H-Index
59
Fully Open Access
Yes
Recent OA Works
1,033
Subject Areas
Psychiatry and Mental healthBiological PsychiatryPharmacology

Source: the current OpenAlex source record. OpenAlex works can include multiple work types. Fully Open Access is a source-level flag. Recent OA Works is summed from OpenAlex's counts_by_year series (up to the latest ten years); it is not a lifetime OA percentage. Any APC shown here is an indicative OpenAlex value—verify current charges on the journal's official website.

How to submit to Clinical Psychopharmacology and Neuroscience

  1. 1

    Check the scope

    OpenAlex classifies Clinical Psychopharmacology and Neuroscience's papers in subfields including Psychiatry and Mental health, Biological Psychiatry, and Pharmacology. Read the aims and scope page and a few recent papers close to your topic before you prepare the manuscript.

  2. 2

    Follow the author guidelines

    Article types, word and figure limits, reference style, and the required statements (data availability, ethics, conflicts of interest, author contributions) are set by the journal. Prepare the cover letter and files to match them.

    Clinical Psychopharmacology and Neuroscience homepage ↗
  3. 3

    Submit online

    Use the submit link in Clinical Psychopharmacology and Neuroscience's author guidelines. Every author usually needs an ORCID iD, and the corresponding author needs an account on the submission site.

  4. 4

    Plan for costs

    The journal is fully open access, and OpenAlex has no article processing charge on record. Check the journal website for current fees and waivers.

  5. 5

    Know what to expect

    Recent accepted papers took a median of 73 days from submission to acceptance, including revisions (PubMed dates). Clinical Psychopharmacology and Neuroscience does not publish an acceptance rate.

New on PubMed

What's new in your field?

Type a topic to see the newest PubMed papers from the past week and the big picture of what they found, summarized by Claude on the Pro plan. Get a free weekly email to keep up.

See a demo:GLP-1CRISPRLong COVID

Reviewer Two · coming soon

Know what reviewers will say before you submit to Clinical Psychopharmacology and Neuroscience

An AI pre-submission report on your manuscript: the objections a tough reviewer is likely to raise, desk-rejection risks, and better-fit journals from our data. $29 per report.

See what the report covers

Common questions about Clinical Psychopharmacology and Neuroscience

Is Clinical Psychopharmacology and Neuroscience a good journal?

By citation data, Clinical Psychopharmacology and Neuroscience is a solid journal: it is Q2 in Psychiatry and Mental health, the second quarter of journals by score, and ranks #625 of 1,171 Neuroscience journals by Journal Metrics Score (top 54%). Clinical Psychopharmacology and Neuroscience's 2026 Journal Metrics Score is 1.8. Recent papers took a median of 73 days from submission to acceptance, according to PubMed dates. OpenAlex classifies its papers in subfields including Psychiatry and Mental health, Biological Psychiatry, and Pharmacology, so check that your topic fits its scope.

What is Clinical Psychopharmacology and Neuroscience's Journal Metrics Score in 2026?

Clinical Psychopharmacology and Neuroscience's 2026 Journal Metrics Score is 1.8, from the August 2026 data release. The score is a two-year citation average computed from OpenAlex (CC0) data: citations received in the most recent complete year to works published in the two prior years, divided by the number of those works.

What is the acceptance rate of Clinical Psychopharmacology and Neuroscience?

We have not found an official acceptance rate published by Clinical Psychopharmacology and Neuroscience or its publisher, and Journal Metrics does not estimate one because submission counts are not public. What recent PubMed records do show is speed: accepted papers took a median of 73 days from submission to acceptance. To judge selectivity, compare Clinical Psychopharmacology and Neuroscience's quartile and score with similar journals, or ask the editorial office.

What quartile is Clinical Psychopharmacology and Neuroscience in?

Clinical Psychopharmacology and Neuroscience's best quartile is Q2. By OpenAlex subfield: Q2 in Psychiatry and Mental health; Q4 in Biological Psychiatry; Q3 in Pharmacology. Quartiles rank journals by Journal Metrics Score within each subfield.

Is the Journal Metrics Score the same as other journal citation metrics?

No. Journal Metrics computes the score independently from OpenAlex open data. Other providers use different citation databases, document types, and counting rules, so their published figures for Clinical Psychopharmacology and Neuroscience will not match this score exactly. Compare journals using one source at a time.

How long does Clinical Psychopharmacology and Neuroscience take from submission to acceptance?

Across 99 recent PubMed records with both dates, Clinical Psychopharmacology and Neuroscience took a median of 73 days from submission to acceptance; the middle half took 42–108 days. This interval includes editorial handling and revisions, so it is not the time to a first decision.

Which journals are alternatives to Clinical Psychopharmacology and Neuroscience?

Comparable journals include International Clinical Psychopharmacology, Journal of Child and Adolescent Psychopharmacology, Psychiatry and Clinical Psychopharmacology, and World Journal of Biological Psychiatry. Compare their scores, acceptance times, and costs in the recommended alternatives on this page before choosing where to submit.

How do I submit a paper to Clinical Psychopharmacology and Neuroscience?

Submit online through the link in Clinical Psychopharmacology and Neuroscience's author guidelines on the journal homepage. Before submitting, check the scope, follow the author guidelines for article type, length, and required statements, and prepare a cover letter. Accepted papers took a median of 73 days from submission to acceptance in recent PubMed records.

Cite an article from this journal
Back to Search